Linifanib

Linifanib

SCHEMBL1880038

Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1.O

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CSF1RFLT1FLT3FLT4KDRPDGFRAPDGFRB

The experimentally established mechanism targets of Linifanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR known ✓ P35968 19/20 0.98
FLT3 known ✓ P36888 16/20 0.98
CSF1R known ✓ P07333 10/20 0.98
FLT4 known ✓ P35916 10/20 0.98
FLT1 known ✓ P17948 9/20 0.98
PDGFRB known ✓ P09619 1/20 0.98
PDGFRA known ✓ P16234 1/20 0.98
KIT P10721 14/20 0.98
LYN P07948 7/20 0.98
SRC P12931 6/20 0.98
BLK P51451 6/20 0.98
AURKA O14965 5/20 0.98
AURKB Q96GD4 5/20 0.98
PLK4 O00444 4/20 0.98
ROCK2 O75116 4/20 0.98
MET P08581 4/20 0.98
PRKACA P17612 4/20 0.98
RPS6KB1 P23443 4/20 0.98
CSNK1D P48730 4/20 0.98
STK3 Q13188 4/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Linifanib SCHEMBL29375368 0.99 KDR (1.00) KDRFLT3KITCSF1RFLT4
Linifanib SCHEMBL93804 0.99 KDR (1.00) KDRFLT3KITCSF1RFLT4
Linifanib SCHEMBL2239943 0.96 KDR (0.94) KDRFLT3KITCSF1RFLT4
SCHEMBL421934 0.90 KDR (0.82) KDRFLT3KITCSF1RFLT4
SCHEMBL420765 0.89 KDR (1.00) KDRFLT3KITCSF1RFLT4
SCHEMBL1662335 0.89 KDR (0.81) KDRFLT3KITCSF1RFLT4
SCHEMBL423705 0.88 KDR (0.80) KDRFLT3KITCSF1RFLT4
SCHEMBL424019 0.88 KDR (0.79) KDRFLT3KITCSF1RFLT4
SCHEMBL1659063 0.88 KDR (0.79) KDRFLT3KITCSF1RFLT4
SCHEMBL6073436 0.88 KDR (0.79) KDRFLT3KITCSF1RFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759538-B1 Crystalline chemotherapeutic ABBVIE INC. (US) 2014-06-24 US claimed
EP-2195298-B1 CRYSTALLINE INDAZOLE-DERIVED CHEMOTHEREPEUTIC ABBVIE BAHAMAS LTD (BS) 2014-02-19 EP claimed
US-8486988-B2 Crystalline chemotherapeutic ABBVIE INC. (US) 2013-07-16 US claimed
US-20110196010-A1 CRYSTALLINE CHEMOTHERAPEUTIC ABBOTT LABORATORIES (US) 2011-08-11 US claimed
US-7947843-B2 Crystalline chemotherapeutic ABBOTT LABORATORIES (US) 2011-05-24 US claimed
EP-2195298-A1 CRYSTALLINE INDAZOLE-DERIVED CHEMOTHEREPEUTIC Abbott Laboratories (US) 2010-06-16 EP claimed
US-20090118344-A1 Crystalline Chemotherapeutic ABBOTT LABORATORIES (US) 2009-05-07 US claimed
WO-2009052226-A1 CRYSTALLINE INDAZOLE-DERIVED CHEMOTHEREPEUTIC ABBOTT LABORATORIES (US) 2009-04-23 WO claimed
US-8759538-B1 Crystalline chemotherapeutic ABBVIE INC. (US) 2014-06-24 US disclosed
US-8759538-B1 Crystalline chemotherapeutic ABBVIE INC. (US) 2014-06-24 US disclosed
EP-2195298-B1 CRYSTALLINE INDAZOLE-DERIVED CHEMOTHEREPEUTIC ABBVIE BAHAMAS LTD (BS) 2014-02-19 EP disclosed
US-8486988-B2 Crystalline chemotherapeutic ABBVIE INC. (US) 2013-07-16 US disclosed
US-8486988-B2 Crystalline chemotherapeutic ABBVIE INC. (US) 2013-07-16 US disclosed
CN-101827822-B Crystalline indazole-derived chemotherepeutic ABBOTT LAB 2013-06-19 CN disclosed
US-20090124816-A1 Crystalline Chemotherapeutic ABBOTT LABORATORIES (US) 2009-05-14 US disclosed
US-20090118344-A1 Crystalline Chemotherapeutic ABBOTT LABORATORIES (US) 2009-05-07 US disclosed
US-20090118344-A1 Crystalline Chemotherapeutic ABBOTT LABORATORIES (US) 2009-05-07 US disclosed
WO-2009052226-A1 CRYSTALLINE INDAZOLE-DERIVED CHEMOTHEREPEUTIC ABBOTT LABORATORIES (US) 2009-04-23 WO disclosed
WO-2009052226-A1 CRYSTALLINE INDAZOLE-DERIVED CHEMOTHEREPEUTIC ABBOTT LABORATORIES (US) 2009-04-23 WO disclosed
WO-2009052231-A1 CRYSTALLINE CHEMOTHERAPEUTIC ABBOTT LABORATORIES (US) 2009-04-23 WO disclosed